SIGA assumes primary responsibility for oral TPOXX promotion; Meridian retains limited rights in EU/UK/AU/JP/CH

SIGA TECHNOLOGIES INC

Amendment to Promotion Agreement effective June 1, 2024; SIGA takes over global advertising, promotion and sale of oral TPOXX.
Meridian retains non-exclusive rights only in European Economic Area, Australia, Japan, Switzerland and the UK.
Meridian receives reduced promotion fee: high single-digit percentage of collected proceeds from Territory sales.
Agreement has fixed term expiring May 31, 2026, with no automatic renewal.

item 1.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SIGA TECHNOLOGIES INC amended Amendment with Meridian Medical Technologies, LLC (effective 2024-03-27).

Action: amendment
Counterparty: Meridian Medical Technologies, LLC
Effective: 2024-03-27

Exact text from the filing

On March 27, 2024, SIGA Technologies, Inc. (the “Company”) and Meridian Medical Technologies, LLC (“Meridian”) entered into an amendment (the “Amendment”) to the Promotion Agreement

View on SEC.gov

292 material agreements filed in the last 30 days. Browse all material agreements →

SIGA TECHNOLOGIES INC filing history →

Source: SEC EDGAR

accession 0001140361-24-016900

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.